t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma

Detalhes bibliográficos
Autor(a) principal: Salles,Terezinha J. Marques
Data de Publicação: 2004
Outros Autores: Costa,Márcia B., Morais,Vera L. L., J. Filho,Romualdo, Magalhães,Mario H., Silva,Maria L. M., Silva,Sandra M. A., Oliveira,Maria S. Pombo de
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842004000200010
Resumo: We report on a 7-year-old girl with Ewing's Sarcoma (ES) who developed a poorly differentiated acute myeloid leukemia (AML-M0) 20 months after beginning the EW92 protocol for the treatment of the primary tumor. She received a total dose of 1500 mg of etoposide, a tumor cumulative radiation dose of 35Gy and granulocyte colony-stimulating factor (G-CSF) was as predicted in the protocol regimen. At onset of secondary malignancy her laboratorial analysis revealed immature blast cells characterized by CD34+/CD33-/a-MPO+ and a t(4;11)(q21;q23) abnormality. This serious complication of ES treatment, which associates etoposide, irradiation and G-CSF schedule, should be weighed against its therapeutic benefits.
id ABHHTC-1_8661b54f6591f43f35aabb37c5ac6c40
oai_identifier_str oai:scielo:S1516-84842004000200010
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcomaTherapy-related acute myeloid leukemiaMLL geneEwing's sarcomaTopoisomerase II inhibitorsG-CSFWe report on a 7-year-old girl with Ewing's Sarcoma (ES) who developed a poorly differentiated acute myeloid leukemia (AML-M0) 20 months after beginning the EW92 protocol for the treatment of the primary tumor. She received a total dose of 1500 mg of etoposide, a tumor cumulative radiation dose of 35Gy and granulocyte colony-stimulating factor (G-CSF) was as predicted in the protocol regimen. At onset of secondary malignancy her laboratorial analysis revealed immature blast cells characterized by CD34+/CD33-/a-MPO+ and a t(4;11)(q21;q23) abnormality. This serious complication of ES treatment, which associates etoposide, irradiation and G-CSF schedule, should be weighed against its therapeutic benefits.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2004-01-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842004000200010Revista Brasileira de Hematologia e Hemoterapia v.26 n.2 2004reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1590/S1516-84842004000200010info:eu-repo/semantics/openAccessSalles,Terezinha J. MarquesCosta,Márcia B.Morais,Vera L. L.J. Filho,RomualdoMagalhães,Mario H.Silva,Maria L. M.Silva,Sandra M. A.Oliveira,Maria S. Pombo deeng2005-03-09T00:00:00Zoai:scielo:S1516-84842004000200010Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2005-03-09T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
title t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
spellingShingle t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
Salles,Terezinha J. Marques
Therapy-related acute myeloid leukemia
MLL gene
Ewing's sarcoma
Topoisomerase II inhibitors
G-CSF
title_short t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
title_full t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
title_fullStr t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
title_full_unstemmed t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
title_sort t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma
author Salles,Terezinha J. Marques
author_facet Salles,Terezinha J. Marques
Costa,Márcia B.
Morais,Vera L. L.
J. Filho,Romualdo
Magalhães,Mario H.
Silva,Maria L. M.
Silva,Sandra M. A.
Oliveira,Maria S. Pombo de
author_role author
author2 Costa,Márcia B.
Morais,Vera L. L.
J. Filho,Romualdo
Magalhães,Mario H.
Silva,Maria L. M.
Silva,Sandra M. A.
Oliveira,Maria S. Pombo de
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Salles,Terezinha J. Marques
Costa,Márcia B.
Morais,Vera L. L.
J. Filho,Romualdo
Magalhães,Mario H.
Silva,Maria L. M.
Silva,Sandra M. A.
Oliveira,Maria S. Pombo de
dc.subject.por.fl_str_mv Therapy-related acute myeloid leukemia
MLL gene
Ewing's sarcoma
Topoisomerase II inhibitors
G-CSF
topic Therapy-related acute myeloid leukemia
MLL gene
Ewing's sarcoma
Topoisomerase II inhibitors
G-CSF
description We report on a 7-year-old girl with Ewing's Sarcoma (ES) who developed a poorly differentiated acute myeloid leukemia (AML-M0) 20 months after beginning the EW92 protocol for the treatment of the primary tumor. She received a total dose of 1500 mg of etoposide, a tumor cumulative radiation dose of 35Gy and granulocyte colony-stimulating factor (G-CSF) was as predicted in the protocol regimen. At onset of secondary malignancy her laboratorial analysis revealed immature blast cells characterized by CD34+/CD33-/a-MPO+ and a t(4;11)(q21;q23) abnormality. This serious complication of ES treatment, which associates etoposide, irradiation and G-CSF schedule, should be weighed against its therapeutic benefits.
publishDate 2004
dc.date.none.fl_str_mv 2004-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842004000200010
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842004000200010
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-84842004000200010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.26 n.2 2004
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213107882786816

Registros relacionados